agilon health, inc.

Listed Company

AGLCIK 0001831097NYSELarge AcceleratedServices-Misc Health & Allied Services, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$5.93B

Net Income

$-391.35M

Total Assets

$1.27B

Equity

$126.73M

Shares Out

414.87M

Op. Cash Flow

$-105.76M

Business

agilon health, inc. transforms healthcare by empowering primary care physicians to manage total care for Medicare patients through an integrated platform and partnership model. It offers a purpose-built technology and services platform, risk-bearing entity support, care management, data analytics, and long-term professional service agreements that enable globally capitated Medicare arrangements and shared savings with physician partners. Its key components include the agilon platform, long-term anchor physician partnerships deployed via local risk-bearing entities, and a collaborative physician network. agilon operates across multiple U.S. geographies through contracts with health plan payors and participation in CMS ACO models, supporting local branding and payor-driven marketing.

Summary from filing dated 2025-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	5,933	6,061	4,316	2,388	1,521
General and administrative	239	269	286	208	428
Depreciation and amortization	29	24	16	9	10
Impairments	36	4	0	0	—
Total expenses	6,396	6,353	4,548	2,494	1,894
Income (loss) from operations	−463	−292	−232	−105	−372
Income (loss) from equity method investments	−2	15	16	11	−7
Other income (expense), net	68	34	28	14	2
Interest expense	−7	−6	−7	−4	—
Income (loss) before income taxes	−404	−249	−194	−91	−383
Income tax benefit (expense)	−1	−1	−791,000	−2	−886,000
Income (loss) from continuing operations	−405	−250	−195	−92	−384
Income (loss) before gain (loss) on sales	0	−1	−20	—	—
Gain (loss) and adjustments on sales of assets, net	14	−9	−48	0	—
Total discontinued operations	14	−10	−68	—	—
Net income (loss)	−391	−260	−263	−107	−407
Noncontrolling interests share in (earnings) loss	0	−50,000	207,000	311,000	300,000
Net income (loss) attributable to common shares	−391	−260	−263	−107	−406
Continuing operations basic (in dollars per share)	−0.98	−0.61	−0.48	−0.22	−1.03
Continuing operations diluted (in dollars per share)	−0.98	−0.61	−0.48	−0.22	−1.03
Discontinued operations basic (in dollars per share)	0.03	−0.02	−0.16	−0.04	−0.06
Discontinued operations diluted (in dollars per share)	0.03	−0.02	−0.16	−0.04	−0.06
Weighted average shares outstanding, basic (in shares)	414	411	409	408	373
Weighted average shares outstanding, diluted (in shares)	414	411	409	408	373

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	174	188	108	465	1,040
Restricted cash and equivalents	0	6	7	11	15
Marketable securities	111	212	381	412	—
Receivables, net	674	1,017	942	492	293
Prepaid expenses and other current assets, net	138	35	43	32	19
Total current assets	1,097	1,458	1,480	1,451	1,367
Property, equipment, and capitalized software, net	25	28	28	20	9
Intangible assets, net	66	73	64	18	55
Goodwill	0	24	24	3	42
Other assets	83	151	145	106	113
Total assets	1,271	1,734	1,741	1,697	1,586
Medical claims and related payables	930	932	738	301	239
Accounts payable and accrued expenses	127	220	239	177	113
Current portion of long-term debt	19	0	6	5	5
Total current liabilities	1,076	1,152	977	535	357
Long-term debt, net of current portion	16	35	32	38	43
Other liabilities	52	76	70	82	94
Total liabilities	1,145	1,263	1,080	657	495
Commitments and contingencies	—	—	—	—	—
Common stock, $0.01 par value: 2,000,000 shares authorized; 414,728 and 412,194 shares issued and outstanding, respectively	4	4	4	4	4
Additional paid-in capital	2,100	2,054	1,987	2,107	2,046
Accumulated deficit	−1,978	−1,587	−1,327	−1,064	−958
Accumulated other comprehensive income (loss)	916,000	−88,000	−2	−6	0
Total stockholders equity (deficit)	127	471	661	1,041	1,092
Total liabilities and stockholders equity (deficit)	1,271	1,734	1,741	1,697	1,586

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	29	24	20	14	15
Stock-based compensation expense	49	51	69	28	292
Distributions of earnings from equity method investments	0	3	0	0	174,000
Gain (loss) and adjustments on sales of assets, net	−14	4	48	0	−473,000
Other, net	−6	887,000	−4	3	58,000
Receivables, net	345	−75	−460	−204	−149
Prepaid expense and other current assets	−65	8	−6	−17	−4
Other assets	−133,000	6,000	−397,000	−205,000	4
Medical claims and related payables	−2	194	442	108	76
Accounts payable and accrued expenses	−86	5	32	66	19
Other liabilities	−2	−2	−17	−12	−2
Net cash provided by (used in) operating activities	−106	−58	−156	−131	−148
Purchase of property and equipment	−13	−13	−16	−15	−7
Purchase of intangible assets	−30	−28	−15	−17	−7
Investments in loans receivable and other	−2	−14	−20	—	—
Investments in marketable securities	−60	−12	−115	−458	0
Proceeds from maturities of marketable securities and other	194	207	164	—	—
Net cash paid in business combination	0	0	−45	0	—
Proceeds from sale of business and property, net of cash divested	0	0	2	500,000	−1
Net cash provided by (used in) investing activities	89	140	−44	−444	−91
Proceeds from (payments for) equity issuances, net	−3	1	12	—	—
Common stock repurchase	0	0	−200	0	0
Repayments of long-term debt	0	−4	−5	−5	−120
Net cash provided by (used in) financing activities	−3	−3	−193	28	1,154
Net increase (decrease) in cash, cash equivalents and restricted cash and equivalents	−20	80	−393	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro